相关实验视频

Updated: Jun 9, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

CVN424,一种GPR6逆agonist,用于帕金森病和运动波动:双盲,随机,第二阶段试验

Nicola L Brice¹, Mark Carlton¹, David H Margolin¹

¹Cerevance, 418 Cambridge Science Park, CB4 0PZ, Cambridge, United Kingdom.

EClinicalMedicine

|October 29, 2024

概括

CVN424是一种GPR6逆agonist,在减少帕金森病 (PD) 患者的OFF时间方面表现有前途. 150毫克的剂量被很好地容忍,并且在与列沃多巴一起使用时,表明每天OFF时间有临床意义的减少.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

帕金森病 (PD) 的特点是运动波动,包括使人虚弱的OFF时间.
利沃多巴是主要的治疗方法,但许多患者会出现残留运动症状.
CVN424是一种选择性GPR6逆激动剂,向间接的条状体通路,提供了一种新的治疗方法.

研究的目的:

评估CVN424的安全性和有效性,作为对利沃多巴的辅助疗法.
评估PD患者经历运动波动的每日OFF时间的减少.

主要方法:

一项随机,双盲,安慰剂控制的研究 (NCT04191577) 涉及141名患有PD的参与者.
参与者每天接受一次CVN424 (50毫克或150毫克) 或安慰剂,持续28天,同时接受稳定的利沃多巴.
主要终点包括安全性和耐受性;关键的次要终点是每天关机时间的变化.

主要成果:

CVN424是安全的,耐受性很好,头痛和恶心是最常见的不良事件.
150毫克的CVN424剂量导致每日OFF时间 (-1.3小时,p=0.02) 经安慰剂调整而显著减少.
在所有组中都没有报告与治疗相关的严重不良事件.

结论:

CVN424,特别是150毫克剂量,是一种安全有效的辅助治疗,可减少PD患者的OFF时间.
这些发现支持CVN424的进一步开发,用于管理帕金森病的运动波动.
这项研究强调了针对GPR6通路用于PD症状管理的潜力.

关键词:

现在的CVN是CVN424 在 GPR6 中使用.间接的路径间接的路径.发动机的波动发动机的波动帕金森病的疾病.状体是一个状体.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...